Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06818773 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer

Name: Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer — clinical trial record (NCT06818773)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 4

SponsorEastern Hepatobiliary Surgery Hospital

Started2025-02

View on ClinicalTrials.gov ↗

Eastern Hepatobiliary Surgery Hospital

15 trials monitored

See 1 trial at risk

Cholangiocarcinoma

611 trials monitored

See 25 trials at risk

HER2-Positive Cancer

324 trials monitored

See 21 trials at risk

To evaluate the efficacy and safety of inetetamab in combination with chemotherapy ± immunotherapy as a first-line treatment for HER2-positive advanced biliary tract cancer, providing theoretical evidence and practical guidance for further optimizing treatment regimens and improving therapeutic outcomes.

Trial Details

NCT Number	NCT06818773
Lead Sponsor	Eastern Hepatobiliary Surgery Hospital
Conditions	Metastatic Biliary Tract Cancer, HER2 Positive
Enrollment	35 participants
Start Date	2025-02
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-02-10